$PHRRF News
Last published 1y ago
- 1y agoPHRRFPharmaTher Provides Corporate Update on Ketamine Development and Commercial StrategyGlobeNewswireTORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical
- 1y agoPHRRFPharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing PaymentsGlobeNewswireTORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical
- 1y agoPHRRFPharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)GlobeNewswireTORONTO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical
- 1y agoPHRRFPharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™)GlobeNewswireTORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of
- 1y agoPHRRFPharmaTher Announces FDA Approval of Ketamine (KETARx™)GlobeNewswireTORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of
- 1y agoPHRRFPharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for KetamineGlobeNewswireTORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company focused on the development and commercialization of
- 1y agoPHRRFPharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar MarketGlobeNewswireTORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB:PHRRF) (CSE:PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine, is
- 1y agoPHRRFPharmaTher Applauds FDA's New Commissioner's National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security ApplicationsGlobeNewswireTORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB:PHRRF) (CSE:PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine,
- 1y agoPHRRFPharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025GlobeNewswireTORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB:PHRRF) (CSE:PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on ketamine for unmet medical
- 1y agoPHRRFPharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and CommercializationGlobeNewswireTORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company focused on the research and commercialization of ketamine
- 1y agoPHRRFPharmaTher Receives US FDA Approval Goal Date for KetamineGlobeNewswireTORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company hyper-focused on the commercialization of Ketamine, is
- 1y agoPHRRFPharmaTher Provides Update on FDA New Drug Application for KetamineGlobeNewswireTORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company seeking FDA approval for ketamine, today announced that
- 1y agoPHRRFPharmaTher CEO Issues Letter to ShareholdersGlobeNewswireTORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company focused on the development and commercialization of
- 1y agoPHRRFPharmaTher Announces Update on FDA New Drug Application for KetamineGlobeNewswireFDA provided preliminary responses to questions contained in the clarification only post-CRL meeting scheduled for December 2, 2024 PharmaTher has decided to cancel the meeting as the FDA preliminary responses were
- 1y agoPHRRFPharmaTher Announces Update on FDA New Drug Application for KetamineGlobeNewswireFDA granted a post-complete letter clarification meeting scheduled for December 2, 2024 Company initiated activities to address the deficiencies cited in the CRL TORONTO, Nov. 19, 2024 (GLOBE NEWSWIRE) --
- 1y agoPHRRFPharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug ApplicationGlobeNewswireTORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, today announced that the Company requested a
- 1y agoPHRRFRVVTFRevive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in StrokeGlobeNewswireTORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
- 2y agoPHRRFPharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug ApplicationGlobeNewswireTORONTO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, today announced that the U.S. Food and Drug
- 2y agoPHRRFPharmaTher Announces Update on FDA New Drug Application for KetamineGlobeNewswireTORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, today announced an update for its New Drug Application
- 2y agoPHRRFPharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for KetamineGlobeNewswireTORONTO, May 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, today announced receipt of an Amendment Acknowledgment
- 2y agoPHRRFPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineGlobeNewswireTORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, today announced receipt of a Complete Response Letter
- 2y agoPHRRFPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineGlobeNewswireTORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated
- 2y agoPHRRFRVVTFRevive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use DisorderGlobeNewswireTORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
- 2y agoPHRRFPharmaTher Provides Update for Expected FDA Approval of KetamineGlobeNewswireTORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, is pleased to provide an update for the Company's lead
- 3y agoPHRRFPharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)GlobeNewswireFDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher's commitment toward unlocking the potential of ketamine for unmet medical needs TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PharmaTher
- 3y agoPHRRFPharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDAGlobeNewswireTORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has
- 3y agoPHRRFPharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo TherapeuticsGlobeNewswireTORONTO, July 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce that it has
- 3y agoPHRRFPharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDAGlobeNewswireTORONTO, June 27, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has filed a
- 3y agoPHRRFPharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.GlobeNewswireTORONTO, June 20, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has entered
- 3y agoPHRRFPharmaTher Holdings Provides Corporate UpdateGlobeNewswireCompany funded to meet upcoming milestones over the next 24 months Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and international approvals after that Company advancing
- 3y agoPHRRFPharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson's DiseaseGlobeNewswireTORONTO, May 02, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, today announced the submission of a Fast Track
- 3y agoPHRRFRVVTFRevive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla BiotechGlobeNewswirePurchased MDMA supply from PharmAla Biotech for upcoming IND-enabling studies Finalizing product and clinical development plans for upcoming studies and potential commercial opportunities TORONTO, April 03, 2023
- 3y agoPHRRFPharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson's DiseaseGlobeNewswireTORONTO, March 29, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, today announced an update on the Type C meeting with
- 3y agoPHRRFPharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump SystemGlobeNewswireTORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd.
- 3y agoPHRRFRVVTFRevive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch DevelopmentGlobeNewswireTORONTO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of
- 3y agoPHRRFRVVTFRevive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal PatchGlobeNewswireTORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
- 3y agoPHRRFPharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett SyndromeGlobeNewswirePharmaTher's 5th FDA orphan drug designation for KETARX™ (ketamine) Phase 2 clinical study results to support proposed Phase 3 development of KETARX™ (ketamine) to treat Rett Syndrome for FDA approval via
- 3y agoPHRRFPharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson's DiseaseGlobeNewswireTORONTO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a leader in advancing specialty ketamine pharmaceuticals, today submitted its meeting
- 3y agoPHRRFPharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett SyndromeGlobeNewswireTORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has applied
- 3y agoPHRRFPharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023GlobeNewswireCompany aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA approvals for KETARX™ via the ANDA and 505(b)(2)
- 3y agoPHRRFPharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ TransplantationGlobeNewswireTORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug
- 3y agoPHRRFPharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease at Neuroscience 2022 by the Society for NeuroscienceGlobeNewswireSeeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine) for Parkinson's disease under the 505(b)(2) regulatory pathway Ketamine was safe, well-tolerated with 100% of
- 4y agoPHRRFPharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett SyndromeGlobeNewswireTORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and
- 4y agoPHRRFPharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson's DiseaseGlobeNewswireGrant of US patent strengthens the PharmaTher's intellectual property portfolio covering novel uses and delivery forms of ketamine Announced positive efficacy and safety data from Phase 1/2 clinical study of ketamine in the treatment of levodopa-induc
- 4y agoPHRRFPharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022GlobeNewswireNearly $12 million in cash and investment Fully funded for the Company's development programs, including ketamine injection and infusion products, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and
- 4y agoPHRRFPharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease at the MDS International Congress of Parkinson's Disease and Movement Disorders®GlobeNewswireKetamine was safe, well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) UDysRS showed a 51% reduction from baseline during Infusion 2 (p=0.003), 4
- 4y agoPHRRFPharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine PatchGlobeNewswireKETARX™ Ketamine Patch demonstrated extended delivery of ketamine over 40 hours KETARX™ Ketamine Patch offers flexible dosing through increased size, drug load or concentration of ketamine to better align with intramuscular and intravenous adminis
- 4y agoPHRRFPharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor DisordersGlobeNewswireTORONTO, July 13, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a leader in specialty ketamine pharmaceuticals, announced today that the United States Patent and Trademark Office ("USPTO") h
- 4y agoPHRRFPharmaTher Announces Positive Results from Study For Ketamine Microneedle PatchGlobeNewswireSuccessfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and pharmacokinetic profiles Pursuing Phase 2 clinical studies in treatment-resistant depression and pain i
- 4y agoPHRRFPharmaTher Announces Positive Results from Study of KETABET™ for DepressionGlobeNewswireKETABET™ (Ketamine and Betaine) shown effectiveness as measured by the Clinician Administered Dissociative States Scale Study results are adequate to give an effect size in powering a placebo-controlled clinical study PharmaTher planning a Phase